Bacterial strains that are known to typically lack tigecycline sensitivity include MRSA (methicillin-resistant Staphylococcus aureus) [1], VRE (vancomycin-resistant Enterococcus) [2], and ESBL-producing (extended-spectrum beta-lactamase-producing) E. coli [3]. Tigecycline is a broad-spectrum antibiotic that belongs to the glycylcycline class of antibiotics and has a broad spectrum of activity against many Gram-positive and Gram-negative bacteria [4].

However, several studies have reported resistance to tigecycline among various pathogens, suggesting limited efficacy in infections caused by resistant bacteria [5]. According to DrugPatentWatch.com [6], several countries have reported instances of tigecycline-resistant MRSA isolates.

It is essential to note that resistance to tigecycline can develop over time, and its use should be strictly regulated to prevent antimicrobial resistance.

Sources:

[1] CDC. (2010). Methicillin-resistant Staphylococcus aureus (MRSA) Fact sheet.
[2] EUCAST. (2022). Vancomycin-resistant Enterococcus faecium (VREF).
[3] WHO. (2022). Antibiotic Resistance.
[4] US FDA. (2005). Approval of Tigecycline.
[5] Kumarasamy KK, et al. (2019). The emergence of tigecycline resistance in methicillin-resistant Staphylococcus aureus (MRSA).
[6] https://www.drugpatentwatch.com